Zacks Research Upgrades Sensei Biotherapeutics (NASDAQ:SNSE) to “Hold”

Sensei Biotherapeutics (NASDAQ:SNSE) was upgraded by Zacks Research to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other research analysts have also recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, December 29th. Wall Street Zen raised Sensei Biotherapeutics to a “hold” rating in a report on Saturday, December 27th. Finally, Leerink Partners began coverage on Sensei Biotherapeutics in a report on Monday. They set an “outperform” rating and a $50.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Sensei Biotherapeutics presently has a consensus rating of “Hold” and an average price target of $40.00.

Sensei Biotherapeutics Trading Up 4.2%

NASDAQ SNSE opened at $31.64 on Tuesday. The stock’s 50 day moving average is $28.78 and its 200 day moving average is $16.43. Sensei Biotherapeutics has a 12 month low of $5.25 and a 12 month high of $36.76. The stock has a market cap of $42.40 million, a PE ratio of -1.90 and a beta of -0.10.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its quarterly earnings results on Monday, March 30th. The company reported ($3.74) EPS for the quarter, topping analysts’ consensus estimates of ($4.81) by $1.07. On average, analysts forecast that Sensei Biotherapeutics will post -2.77 EPS for the current fiscal year.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC raised its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.